open ai

Musk vs. OpenAI: Court Battle Over AI’s Founding Mission Begins

A closely watched courtroom fight over the direction of artificial intelligence kicked off Tuesday, as Elon Musk appeared in federal court to press his case against OpenAI.

Even before proceedings began, Musk was waging a parallel battle online. On Monday, he posted more than 2 dozen times on X, the social media platform he owns, criticizing OpenAI and its leadership while framing the dispute for his nearly 240 million followers.

The dispute, playing out in Oakland, goes beyond a typical business disagreement. At its core is a fundamental question. Should advanced AI be developed as a public good, or is a profit-driven model inevitable in a field that demands staggering levels of capital?

Musk argues that OpenAI has drifted far from the principles that defined its founding. When the organization launched in 2015, it was framed as a nonprofit research lab committed to advancing artificial intelligence for the benefit of humanity. According to court filings, that vision and the promise that its technology “would belong to the world” were central to convincing Musk to invest millions and lend his name as a co-founder.

Today, OpenAI operates under a hybrid structure in which a nonprofit entity oversees a for-profit arm, an arrangement the company says was necessary to compete in a sector that requires massive spending on data centers, talent, and computing power.

Musk sees that shift differently. In his lawsuit, he claims he was misled about the company’s long-term intentions and that the pivot toward commercialization amounts to a betrayal of its original mission. He is expected to take the stand during the trial, which could unfold over the coming weeks.

Embed from Getty Images

The case also highlights Musk’s increasingly direct competition with OpenAI. Through his company xAI, he has entered the race to build next-generation AI systems, including the chatbot Grok, positioning himself against one of the field’s most influential players.

Across the aisle is Sam Altman, OpenAI’s chief executive and once a collaborator of Musk’s. Their relationship has since deteriorated into a high-profile rivalry that blends personal tension with competing visions for the technology’s future.

OpenAI has pushed back forcefully against Musk’s claims in recent posts on X. In legal filings and public statements, the company argued that Musk’s departure from the organization had less to do with philosophical differences and more to do with disagreements over control.

“The truth is that this case has always been about Elon generating more power and more money for what he wants. Having increasingly realized that his attempt to damage the nonprofit OpenAI Foundation rests on a baseless legal case, Elon is once again trying to change the narrative and save face as the trial approaches. His lawsuit remains nothing more than a harassment campaign that’s driven by ego, jealousy and a desire to slow down a competitor.”

Attorneys for OpenAI have maintained that the company’s leadership, including Altman and co-founder Greg Brockman, stands firmly behind its decisions. They “are confident in their position and look forward to the facts being known,” lawyer William Savitt said after jury selection concluded.

Still, Musk’s legal challenge is sweeping in scope. He is seeking structural changes that would force OpenAI to return to a purely nonprofit model, as well as the removal of key executives. While he initially sought damages of up to $134 billion, Musk has since said he would redirect any financial award to the organization’s nonprofit arm rather than keep it.

Embed from Getty Images

As governments and companies worldwide grapple with how to regulate and fund artificial intelligence, the trial highlights a growing divide between those who see AI as a public utility and those who view it as a competitive industry driven by private investment.

Presiding over the case is Judge Yvonne Gonzalez Rogers, who will ultimately decide the remedy, if any, after considering input from an advisory jury. A decision is expected by late May.

On the eve of the trial, Musk took direct aim at Altman on social media, calling him “Scam Altman,” a jab that underscores how a once-collaborative partnership has evolved into one of Silicon Valley’s most consequential feuds.

“Scam Altman and Greg Stockman stole a charity. Greg got tens of billions of stock for himself, and Scam got dozens of OpenAI side deals with a piece of the action for himself.”

During Tuesday’s proceedings, Judge Rogers raised concerns about Musk’s online activity, calling him to the bench to discuss whether to place limits on his public commentary. “How can we get things done without you making things worse outside the courtroom?” she asked.

After Musk said he was responding to statements from OpenAI, the judge urged him, Altman, and Brockman to begin with a “clean slate” and to “keep things to a minimum” on social media. They agreed.

His use of X reflects a broader pattern of shaping public narratives around high-profile disputes, even as jurors in such cases are typically instructed to avoid outside information.

Musk also amplified supportive commentary, including reposting a message that read, “The main difference between Elon Musk and Sam Altman: Elon Musk actually changes the world for the better and saves lives. Sam Altman? He mostly just takes.”

Bonnye Matthews Author

Protected: The Source Of Learning, Education, And Joy Is Work | Bonnye Matthews 

There is no excerpt because this is a protected post.

Dr. Lin Morel Beyond Words Group

Protected: Healing Trauma Through Martial Arts and Spirit | Dr. Lin Morel

There is no excerpt because this is a protected post.

Mallory O'Connor Firehorse

Protected: Environmental Degradation, Loss, And The Supernatural | Firehorse, Mallory O’Connor

There is no excerpt because this is a protected post.

Suzanne Moore Elder Care

Protected: Faith, Family, and Root Beer Floats: Redefining Elder Care | Suzanne Moore

There is no excerpt because this is a protected post.

Dr. Ellen Jane Killebrew

Protected: A Life of Resilience, Innovation, and Advocacy | Dr. Ellen Jane Killebrew

There is no excerpt because this is a protected post.

Susan Matorin

Protected: A Legacy of Leadership and Dedication in Social Work | Susan Matorin

There is no excerpt because this is a protected post.

birds

Trump Administration Terminates Moderna Bird Flu Vaccine Deal, Undermining Pandemic Preparedness

In a striking reversal of pandemic preparedness efforts, the Trump administration has canceled a $600 million contract with Moderna aimed at developing a human vaccine against H5N1 bird flu—a virus with the potential to spark a national outbreak.

The termination also scrapped a key provision granting the U.S. priority access to doses in the event of a pandemic, dismantling an agreement crafted under the Biden administration to boost national readiness against the evolving bird flu threat. The Moderna initiative had expanded on a $175 million government investment made in 2023.

Although the Department of Health and Human Services (HHS) had signaled earlier this year that the contract was under review, the cancellation has still raised alarms across the scientific and public health communities.

Health Secretary Robert F. Kennedy Jr., who has long questioned the safety of mRNA vaccine technology, played a role in the decision. Moderna’s vaccine design relied on mRNA, the same technology used successfully in Pfizer-BioNTech and Moderna’s COVID-19 shots, to prime the immune system by delivering a coded message to produce a harmless piece of the virus.

After what it described as a “rigorous review,” the HHS said it found “continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable,” according to department spokesman Andrew Nixon.

Moderna, for its part, defended the project and the underlying mRNA platform. The biotech company said it would continue exploring other avenues to develop vaccines targeting potentially pandemic-level influenza strains.

Embed from Getty Images

“Results during the pandemic speak for themselves, including demonstrated efficacy and a safety profile established in over a billion people worldwide.”

Public health experts are calling the decision short-sighted, particularly given the nature of bird flu’s current spread. The highly pathogenic H5N1 virus has been detected globally in wild birds, poultry, mammals such as bears and sea lions, and most recently, dairy cattle. Since arriving in the U.S. in 2022, it has triggered the culling of more than 173 million birds and infected over 1,000 cattle herds across 17 states.

At least 70 human cases have been reported, with the majority involving farm or dairy workers. One fatality occurred in January in Louisiana, involving an older adult exposed to infected backyard birds, the first known U.S. death tied to the virus.

While H5N1 has not yet shown sustained human-to-human transmission, virologists warn it could mutate and become highly contagious, underscoring the urgent need for adaptable vaccine platforms. Existing stockpiles of bird flu vaccines are limited and may not offer sufficient protection against future variants.

“Pandemic preparedness is about being proactive, fast and adaptable — the mRNA vaccine platform is all of that,” Dr. Amesh Adalja, an infectious disease physician and senior scholar at the Johns Hopkins Center for Health Security, told The New York Times.

“The rationale given is likely fabricated and more of a function of R.F.K. Jr.’s assault on vaccines, the value of which he evades. Canceling this contract makes the world less safe.”

Embed from Getty Images

Jennifer Nuzzo, who leads the Pandemic Center at Brown University, echoed that concern.

“When the next flu pandemic occurs, there is not going to be enough vaccine for everyone who wants it unless we invest to broaden the types of flu vaccines being made and the number of companies that make them. We shouldn’t let politically motivated attempts to unfairly brand mRNA vaccines as dangerous stand in the way of ensuring everyone who wants a pandemic vaccine can get one.”

Critics attribute Kennedy’s unconventional views on disease management as a key factor in the administration’s decision. In a recent interview, he suggested that farmers allow bird flu to run through flocks to study birds that survive the illness for the source of their immunity — an approach many scientists describe as both unethical and dangerous.

Last week, Kennedy publicly urged Canada to halt the planned euthanasia of 400 ostriches exposed to H5N1. Dr. Mehmet Oz, who heads Medicare and Medicaid services, even offered to relocate the birds to his Florida ranch.

Kennedy has a long history of promoting vaccine skepticism, especially toward mRNA vaccines, which he has falsely claimed are the “deadliest” ever developed. Such assertions starkly contradict a broad scientific consensus.

Currently, the federal government holds three other contracts focused on avian flu vaccine development. Still, the Moderna cancellation deals a significant blow to the push for faster, more agile pandemic response tools — and signals a broader resistance within the administration to emerging vaccine technologies.

Gayle Faulkner Artist

Protected: Celebrating Life Through Art and Creating A Sanctuary Between Artist And Viewer | Gayle Faulkner 

There is no excerpt because this is a protected post.

Protected: Sea Change in Historical Salvation Theology: Could Another Sea Change Occur? | Dr. Don Elijah Eckhart

There is no excerpt because this is a protected post.